人尿激肽原酶联合依达拉奉治疗脑栓塞的效果及对患者神经功能的影响  

Effect of human urinary kallidinogenase combined with edaravone in the treatment of cerebral embolism and its influence on neurological function of patients

作　　者：朱宏静 ZHU Hong-jing;REN Xue-min(Northeast International Hospital,Shenyang 110167,China)

机构地区：[1]东北国际医院,110167

出　　处：《中国实用医药》2022年第1期115-117,共3页China Practical Medicine

摘　　要：目的探讨依达拉奉联合人尿激肽原酶治疗脑栓塞患者的疗效以及对其神经功能的影响。方法98例脑栓塞患者,以治疗方案不同分为常规组及实验组,每组49例。常规组予以依达拉奉治疗,实验组在常规组基础上加入人尿激肽原酶治疗。比较两组疗效、用药不良反应发生情况及治疗前后神经功能缺损情况及生活能力改善情况。结果实验组总有效率95.9%高于常规组的81.6%,差异有统计学意义(P<0.05)。治疗后,两组美国国立卫生研究院卒中量表(NIHSS)评分均低于本组治疗前,Barthel指数均高于本组治疗前,且实验组NIHSS评分(9.03±1.48)分低于常规组的(12.75±2.62)分,Barthel指数(82.44±3.85)分高于常规组的(73.65±4.38)分,差异具有统计学意义(P<0.05)。实验组不良反应发生率4.1%低于常规组的16.3%,差异有统计学意义(P<0.05)。结论以依达拉奉联合人尿激肽原酶治疗脑栓塞患者可取得确切效果的同时还具备较高安全性,值得推广。Objective To discuss the efficacy of human urinary kallidinogenase combined with edaravone in the treatment of cerebral embolism and its influence on neurological function of patients.Methods A total of 98 patients with cerebral embolism were divided into conventional group and experimental group according to different treatment plans,with 49 cases in each group.The conventional group was treated with edaravone,and the experimental group was treated with human urinary kallidinogenase on the basis of the conventional group.The efficacy,occurrence of adverse drug reactions,the neurological deficits and improvement of living ability before and after treatment were compared between the two groups.Results The total effective rate 95.9%of the experimental group was higher than 81.6%of the conventional group,and the difference was statistically significant(P<0.05).After treatment,the National Institutes of Health stroke scale(NIHSS)score of the two groups were lower than those of this group before treatment,and the Barthel index was higher than that of this group before treatment;the NIHSS score(9.03±1.48)points of the experimental group was lower than(12.75±2.62)points of the conventional group,and the Barthel index(82.44±3.85)points was higher than(73.65±4.38)points of the conventional group;all the differences were statistically significant(P<0.05).The incidence of adverse reactions of the experimental group was 4.1%,which was lower than 16.3%of the conventional group,and the difference was statistically significant(P<0.05).Conclusion Edaravone combined with human urinary kallidinogenase in the treatment of patients with cerebral embolism can achieve definite effect,but also has high safety,which is worthy of promotion.

关 键 词：依达拉奉 人尿激肽原酶 脑栓塞 神经功能 不良反应 生活能力 疗效 

分 类 号：R743.33[医药卫生—神经病学与精神病学]